BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) Stock Now Rated “Moderate Buy” by Sell-Side Analysts

Posted by Brenda Bartman on Oct 31st, 2026

BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC – Get Free Report) has been assigned a consensus recommendation of “Moderate Buy” from the seventeen ratings firms that are currently covering the stock, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has issued a strong buy rating on the company. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is $412.26.

A number of equities analysts have issued reports on ONC shares. Wall Street Zen upgraded BeOne Medicines from a “buy” rating to a “strong-buy” rating in a report on Saturday, July 18th. Weiss Ratings upgraded BeOne Medicines from a “hold (c+)” rating to a “buy (b-)” rating in a report on Thursday, October 8th. Royal Bank Of Canada upped their price objective on BeOne Medicines from $450.00 to $459.00 and gave the stock an “outperform” rating in a research report on Thursday, October 8th. Citigroup reiterated an “outperform” rating on shares of BeOne Medicines in a report on Thursday, August 6th. Finally, Citizens Jmp increased their price objective on BeOne Medicines from $396.00 to $405.00 and gave the stock a “market outperform” rating in a report on Thursday, August 6th.

View Our Latest Stock Report on BeOne Medicines

Insider Transactions at BeOne Medicines

In other BeOne Medicines news, CEO John Oyler sold 115,011 shares of the company’s stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $357.87, for a total transaction of $41,158,986.57. Following the completion of the transaction, the chief executive officer owned 125,799 shares of the company’s stock, valued at $45,019,688.13. This represents a 47.76% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Xiaodong Wang sold 38,287 shares of the firm’s stock in a transaction that occurred on Tuesday, September 8th. The stock was sold at an average price of $349.10, for a total transaction of $13,365,991.70. Following the transaction, the insider directly owned 6,079 shares of the company’s stock, valued at $2,122,178.90. This represents a 86.30% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 377,530 shares of company stock worth $135,209,959. Insiders own 6.19% of the company’s stock.

Institutional Trading of BeOne Medicines

Institutional investors and hedge funds have recently bought and sold shares of the stock. Bank of America Corp DE boosted its stake in shares of BeOne Medicines by 7.0% in the 1st quarter. Bank of America Corp DE now owns 405,273 shares of the company’s stock valued at $120,354,000 after purchasing an additional 26,441 shares during the last quarter. Baird Financial Group Inc. increased its position in shares of BeOne Medicines by 5.5% during the second quarter. Baird Financial Group Inc. now owns 368,978 shares of the company’s stock valued at $105,148,000 after acquiring an additional 19,327 shares during the last quarter. Candriam S.C.A. raised its stake in shares of BeOne Medicines by 31.7% during the 1st quarter. Candriam S.C.A. now owns 259,731 shares of the company’s stock worth $77,132,000 after purchasing an additional 62,470 shares during the period. First Trust Advisors LP grew its position in shares of BeOne Medicines by 91.9% during the 1st quarter. First Trust Advisors LP now owns 241,426 shares of the company’s stock valued at $71,696,000 after acquiring an additional 115,601 shares during the period. Finally, Jennison Associates LLC increased its position in BeOne Medicines by 102.1% in the first quarter. Jennison Associates LLC now owns 154,465 shares of the company’s stock worth $45,871,000 after buying an additional 78,027 shares during the last quarter. Institutional investors own 48.55% of the company’s stock.

BeOne Medicines Stock Performance

Shares of NASDAQ:ONC opened at $370.33 on Monday. The company has a market capitalization of $40.66 billion, a price-to-earnings ratio of 65.20 and a beta of 0.61. The firm’s 50 day simple moving average is $363.15 and its 200 day simple moving average is $325.44. The company has a debt-to-equity ratio of 0.17, a current ratio of 3.40 and a quick ratio of 3.06. BeOne Medicines has a fifty-two week low of $253.95 and a fifty-two week high of $388.66.

BeOne Medicines (NASDAQ:ONC – Get Free Report) last released its quarterly earnings data on Wednesday, August 5th. The company reported $2.05 earnings per share for the quarter, topping the consensus estimate of $1.40 by $0.65. BeOne Medicines had a net margin of 10.70% and a return on equity of 14.23%. The business had revenue of $1.71 billion for the quarter, compared to analyst estimates of $1.66 billion. As a group, sell-side analysts forecast that BeOne Medicines will post 8.99 earnings per share for the current year.

About BeOne Medicines

(Get Free Report)

BeOne Medicines Ltd. is a global oncology company focused on discovering, developing, manufacturing and commercializing medicines for cancer patients. Formerly known as BeiGene, the company operates an integrated biotechnology platform spanning research, clinical development, regulatory activities and commercial operations.

Its portfolio includes BRUKINSA (zanubrutinib), a Bruton’s tyrosine kinase inhibitor used in the treatment of several blood cancers, and TEVIMBRA (tislelizumab), an anti-PD-1 immunotherapy approved in multiple markets for certain cancers.